Company research / LNTH

Lantheus Holdings, Inc. (LNTH)

CIK 0001521036 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Lantheus Holdings, Inc. reported revenue of $1.54B. Revenue grew 0.5% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $1.56B.

Key ratios (year ended 2025-12-31)

61.1%
Gross margin
20.2%
Operating margin
15.2%
Net margin
21.4%
Return on year-end equity
0.5%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.56B$1.54B$1.53B$1.30B$935.06M$425.21M$339.41M$347.34M$343.37M$331.38M$301.85M
Cost of Revenue$620.29M$599.66M$545.62M$586.89M$353.36M$237.51M$200.65M$172.53M$168.49M$169.24M$164.07M
Gross Profit$936.02M$941.95M$988.29M$709.54M$581.70M$187.69M$138.76M$174.81M$174.88M$162.13M$137.78M
R&D Expense$173.09M$177.31M$168.10M$77.71M$311.68M$44.97M$32.79M$20.02M$17.07M$18.12M$12.20M
Operating Income$302.34M$310.83M$456.98M$364.64M$36.20M-$60.83M-$4.20M$51.66M$64.49M$51.85M$56.59M
Depreciation & Amortization$88.51M$70.10M$64.62M$60.04M$47.93M$42.29M$24.69M$13.38M$13.93M$19.23M$18.26M
EBITDA$390.85M$380.93M$521.60M$424.69M$84.12M-$18.54M$20.49M$65.04M$78.42M$71.08M$74.85M
Net Income$275.31M$233.56M$312.44M$326.66M$28.07M-$71.28M-$13.47M$31.67M$40.52M$123.39Mn/a
EPS (Diluted)n/a$3.41$4.36$4.65$0.40-$1.06-$0.25$0.79$1.03$3.17$0.82
Total Assets$2.41B$2.23B$1.98B$1.65B$1.32B$863.78M$869.82M$405.92M$439.83M$383.86M$255.90M
Total Liabilities$1.10B$1.14B$892.33M$835.26M$874.11M$399.35M$355.62M$291.32M$368.83M$360.57M$362.41M
Long-Term Debtn/an/an/an/a$558.07M$174.76M$218.40M$194.07Mn/an/an/a
Shareholders' Equity$1.31B$1.09B$1.09B$815.89M$447.15M$464.44M$514.21M$114.60M$71.00M$23.29M-$106.52M
Cash & Equivalents$593.30M$359.12M$912.81M$713.66M$415.65M$98.51M$79.61M$92.92M$113.40M$76.29M$51.18M
Operating Cash Flow$412.80M$390.14M$544.75M$305.26M$281.78M$53.92M$16.40M$80.38M$61.19M$54.78M$49.64M
Capital Expendituresn/an/an/a$45.34M$260.00M$0$0$22.06M$20.13M$17.54M$7.40M
Free Cash Flown/an/an/a$259.92M$21.78M$53.92M$16.40M$58.32M$41.06M$37.23M$42.24M
Share Repurchases$200.02M$300.02M$100.00M$0$75.00M$0$0n/an/an/an/a
Shares Outstanding65.27M64.59M68.45M69.86M68.85M67.74M66.88M39.25M39.25M38.47M37.77M
Weighted Average Diluted Sharesn/a68.44M71.65M70.24M70.67M67.49M54.13M40.11M39.50M38.89M32.66M
EPS (Basic)n/a$3.46$4.52$4.79$0.41-$1.06-$0.25$0.81$1.06$3.31$0.84

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView